Carmen Bozic

Vertex Pharmaceuticals (United States) — United States

Medicine · Health Sciences

19h-index3.2kcitations65works16.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Polyomavirus and related diseases(18), Multiple Sclerosis Research Studies(10), Acute Lymphoblastic Leukemia research(7), Full-Duplex Wireless Communications(7), Inflammatory Bowel Disease(5)

Publications65 total

Suzetrigine for the Treatment of Acute Pain: Reply
Anesthesiology·2025Open Access
Suzetrigine, a Selective Pain Signal Inhibitor of NaV1.8 Shows Proof-of-concept for Treatment of Painful Diabetic Peripheral Neuropathy (S11.002)
Neurology·2025· 4 cited
Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials
Anesthesiology·2025· 31 citedOpen Access
Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain
Journal of Pain Research·2025· 33 citedOpen Access
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
Journal of Cystic Fibrosis·2025· 16 citedOpen Access
Selective Inhibition of Na <sub>V</sub> 1.8 with VX-548 for Acute Pain
New England Journal of Medicine·2023· 224 cited
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
Journal of NeuroVirology·2015· 95 citedOpen Access
Outcome and survival of asymptomatic <scp>PML</scp> in natalizumab‐treated <scp>MS</scp> patients
Annals of Clinical and Translational Neurology·2014· 124 citedOpen Access
Anti‐<scp>JC</scp> virus (<scp>JCV</scp>) antibody prevalence in the <scp>JCV</scp> Epidemiology in <scp>MS</scp> (<scp>JEMS</scp>) trial
European Journal of Neurology·2013· 98 cited
Manufacturer's Response to Case Reports of PML
New England Journal of Medicine·2013· 94 citedOpen Access
Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry (P02.127)
Neurology·2013· 26 cited
Natalizumab Use in Patients With Crohnʼs Disease (CD) and Relapsing Multiple Sclerosis (MS): Updated Utilization and Safety Results
Inflammatory Bowel Diseases·2012· 2 citedOpen Access
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Survey of Anesthesiology·2012· 15 cited
JCV Epidemiology in MS (JEMS): prevalence of anti-JC virus antibodies in multiple sclerosis patients
2012· 1 cited
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
New England Journal of Medicine·2012· 1.2k citedOpen Access
Mo1050 Natalizumab use in Patients With Crohn's Disease and Relapsing Multiple Sclerosis: Updated Utilization and Safety Results From the Touch(r) Prescribing Program, the Pregnancy Registry, and the INFORM and TYGRIS Studies
Gastroenterology·2012· 1 citedOpen Access
Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)
Neurology·2012· 20 cited
Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)
Neurology·2012· 4 cited
Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)
Neurology·2012
Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Annals of Neurology·2011· 141 cited
page 1 of 4Next →

Frequent Co-authors

Gary Bloomgren(11), Sandra Richman(10), Tatiana Plavina(6), Alfred Sandrock(6), Mariska Kooijmans(6), Meena Subramanyam(5), Gráinne Quinn(5), Tuan Dong‐Si(4), N Genton(4), Lynda M. Cristiano(4), Sophia Lee(3), James Scanlon(3), Darin Correll(3), Xiaopeng Miao(3), Todd Bertoch(3), Scott G. Weiner(3), Paul A. Negulescu(3), Nancy Richert(3), Barry Ticho(3), Michael Panzara(3)